tuberculosis
COVID-19 Still a Focus for Infectious Disease Test Developers in 2022, but Ceded Some Ground
Premium
Tests for other respiratory viruses, as well as sexually transmitted infections and tuberculosis, moved back into the development pipeline last year.
LumiraDx Gets $14.2M in Gates Foundation Grants to Develop Point-of-Care Molecular TB Test
The test, which is being designed for use with the company's LumiraDx point-of-care platform, would be the first molecular test to run on the system.
FIND, Policy Cures Research Report Finds Dx R&D Investments Lag Behind Rest of Healthcare
The report also found that a coordinated global effort is required to offer the funding needed to address the gap.
Cowen Upgrades PerkinElmer Stock to Outperform
Analyst Max Masucci said the firm is expected to generate at least $3.21 billion in COVID-19-related revenues, while he lowered the stock price target to $164 per share.
Illumina, GenoScreen Partner to Comarket Genomic Testing for Multidrug-Resistant TB
The firms will comarket Illumina next-generation sequencing reagents with GenoScreen's Deeplex Myc-TB NGS-based test for antibiotic resistance in TB.